Delineating the impact of DIS3 perturbation has become of medical importance over the past decade as DIS3 mutations have been identified in roughly 11% of multiple myeloma (MM) patients, particularly within the exonuclease domain [6]. The gene discussed is DIS3; the disease is Miyoshi myopathy.